Janney Montgomery Scott LLC Takes $1.89 Million Position in Jazz Pharmaceuticals PLC (NASDAQ:JAZZ)

Janney Montgomery Scott LLC purchased a new stake in shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ - Free Report) during the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm purchased 15,210 shares of the specialty pharmaceutical company's stock, valued at approximately $1,888,000.

Several other hedge funds and other institutional investors also recently made changes to their positions in JAZZ. IFP Advisors Inc acquired a new stake in Jazz Pharmaceuticals during the 4th quarter worth approximately $25,000. Bank of New York Mellon Corp raised its stake in shares of Jazz Pharmaceuticals by 5.4% during the fourth quarter. Bank of New York Mellon Corp now owns 477,751 shares of the specialty pharmaceutical company's stock valued at $58,835,000 after acquiring an additional 24,481 shares during the last quarter. Oppenheimer Asset Management Inc. lifted its holdings in shares of Jazz Pharmaceuticals by 24.2% during the fourth quarter. Oppenheimer Asset Management Inc. now owns 9,588 shares of the specialty pharmaceutical company's stock worth $1,181,000 after purchasing an additional 1,867 shares during the period. Proficio Capital Partners LLC bought a new stake in shares of Jazz Pharmaceuticals in the fourth quarter worth $4,762,000. Finally, GW&K Investment Management LLC grew its stake in shares of Jazz Pharmaceuticals by 26.6% in the fourth quarter. GW&K Investment Management LLC now owns 464,003 shares of the specialty pharmaceutical company's stock worth $57,142,000 after purchasing an additional 97,589 shares during the last quarter. 89.14% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several research analysts recently issued reports on the company. HC Wainwright raised their target price on Jazz Pharmaceuticals from $200.00 to $217.00 and gave the stock a "buy" rating in a research report on Monday, March 10th. UBS Group upgraded Jazz Pharmaceuticals from a "neutral" rating to a "buy" rating and raised their price objective for the stock from $145.00 to $179.00 in a research report on Friday, March 7th. Robert W. Baird reduced their target price on Jazz Pharmaceuticals from $167.00 to $155.00 and set an "outperform" rating on the stock in a report on Wednesday, May 7th. Truist Financial increased their target price on shares of Jazz Pharmaceuticals from $220.00 to $230.00 and gave the company a "buy" rating in a research report on Thursday, March 6th. Finally, Needham & Company LLC restated a "buy" rating and set a $202.00 price target on shares of Jazz Pharmaceuticals in a report on Wednesday, June 11th. Two research analysts have rated the stock with a hold rating and twelve have given a buy rating to the company. According to MarketBeat.com, Jazz Pharmaceuticals currently has an average rating of "Moderate Buy" and a consensus target price of $184.00.

Jazz Pharmaceuticals Trading Down 0.7%

JAZZ traded down $0.78 during trading on Monday, hitting $106.12. The company's stock had a trading volume of 728,509 shares, compared to its average volume of 825,856. The firm has a market capitalization of $6.42 billion, a P/E ratio of 14.15, a PEG ratio of 4.61 and a beta of 0.33. Jazz Pharmaceuticals PLC has a twelve month low of $95.49 and a twelve month high of $148.06. The stock's fifty day moving average price is $108.75 and its 200-day moving average price is $119.42. The company has a quick ratio of 2.97, a current ratio of 3.38 and a debt-to-equity ratio of 1.28.

Jazz Pharmaceuticals (NASDAQ:JAZZ - Get Free Report) last released its earnings results on Tuesday, May 6th. The specialty pharmaceutical company reported $1.68 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $4.65 by ($2.97). The company had revenue of $897.84 million for the quarter, compared to analyst estimates of $984.16 million. Jazz Pharmaceuticals had a net margin of 11.86% and a return on equity of 26.62%. The firm's revenue was down .5% on a year-over-year basis. During the same quarter in the previous year, the firm earned $2.68 EPS. Analysts anticipate that Jazz Pharmaceuticals PLC will post 16.96 EPS for the current year.

Insider Activity

In other news, Director Seamus Mulligan purchased 1,621 shares of the company's stock in a transaction that occurred on Monday, May 12th. The shares were acquired at an average cost of $103.00 per share, with a total value of $166,963.00. Following the purchase, the director owned 101,621 shares in the company, valued at $10,466,963. This represents a 1.62% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CEO Bruce C. Cozadd sold 500 shares of the firm's stock in a transaction that occurred on Monday, June 2nd. The shares were sold at an average price of $107.90, for a total value of $53,950.00. Following the completion of the sale, the chief executive officer directly owned 438,473 shares of the company's stock, valued at $47,311,236.70. This trade represents a 0.11% decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 3,000 shares of company stock valued at $355,925. 4.30% of the stock is currently owned by company insiders.

Jazz Pharmaceuticals Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.